Poster Walk and Get Together 3
Disease models, drug development

Programme

• • Poster Self-Study
  • P027

  Heart-directed overexpression of the PP2A regulatory subunit PR72 resulted in premature ischemic contracture but preserved contractility during reperfusion

  • Lars Schmidt (Münster / DE)

   Disease models, drug development
• • Poster Self-Study
  • P028

  Recombinant CTRPs exert anti-apoptotic and anti-hypertrophic effects in cardiomyocytes

  • Constanze Schanbacher (Würzburg / DE)

   Disease models, drug development
• • Poster Self-Study
  • P029

  cGMP-dependent PDE2 activation as a potential antiarrhythmic therapy strategy in heart failure

  • Rebecca Firneburg (Dresden / DE)

   Disease models, drug development
• • Poster Self-Study
  • P030

  Pharmacological reversal of behavioural and microglial aberrancies in a model of high trait anxiety

  • Simone B. Sartori (Innsbruck / AT)

   Disease models, drug development
• • Poster Self-Study
  • P031

  Proteome analysis of mouse retinas carrying pathogenic Cav1.4 L-type calcium channel variants

  • Matthias Ganglberger (Innsbruck / AT)

   Disease models, drug development
• • Poster Self-Study
  • P032

  Do the isoforms of the human farnesyltransferase have unique functions and response to respective inhibitors?

  • Anna Hagemann (Witten / DE)

   Disease models, drug development
• • Poster Self-Study
  • P033

  ­­SMAD4 maintains the Fluid Shear Stress set point to protect against Arterial-Venous Malformations

  • Roxana Ola (Mannheim / DE)

   Disease models, drug development
• • Poster Self-Study
  • P034

  cellasys #8: An assay for monitoring metabolism and morphology of organ-models in real-time

  • Joachim Wiest (Kronburg / DE)

   Disease models, drug development
• • Poster Self-Study
  • P035

  Neuronal processing of hypercapnia-induced anxiety in a model of high trait anxiety

  • Nino Kobakhidze (Innsbruck / AT)

   Disease models, drug development
• • Poster Self-Study
  • P036

  Investigating the active centrum of the humane farnesyltransferase β-subunit for a better druggability

  • Tobias Wellbrock (Witten / DE)

   Disease models, drug development
• • Poster Self-Study
  • P037

  "From Drugs to Drugs": History of Neosalvarsan as chemical starting lead for numerous pharmacological classes with diverse pharmacological activities and clinical indications in the 20th century

  • Hubert Heuer (Schwabenheim / DE)

   Disease models, drug development
• • Poster Self-Study
  • P038

  Dissecting the in vivo role of X-linked lncRNA loci with conserved sex- and allele-specific epigenetic signatures

  • Tim Hasenbein (Munich / DE)

   Disease models, drug development
• • Poster Self-Study
  • P039

  Transneuronal delivery of designer-cytokine enables functional recovery after severe chronic spinal cord injury in mice

  • Marco Leibinger (Cologne / DE)

   Disease models, drug development
• • Poster Self-Study
  • P040

  Reduced CRMP2 activity by p35/CDK5 compromises nerve regeneration in diabetes

  • Philipp Gobrecht (Cologne / DE)

   Disease models, drug development
• • Poster Self-Study
  • P041

  The lncRNA landscape of cardiac resident macrophages and identification of Schlafenlnc as a regulator of macrophage migratory function

  • Anne Dueck (Munich / DE)

   Disease models, drug development
• • Poster Self-Study
  • P042

  Receptor of Hyaluronan-Mediated Motility (RHAMM) confers protection after acute cardiac ischemia

  • Angelika Pastuschka (Düsseldorf / DE)

   Disease models, drug development
• • Poster Self-Study
  • P043

  Novel selenium compounds acting as potent inhibitors of ferroptosis

  • Melanie Merkel (Marburg / DE)

   Disease models, drug development
• • Poster Self-Study
  • P044

  Sympathetic denervation of the pineal gland in heart disease

  • Karin Ziegler (Munich / DE)

   Disease models, drug development
• • Poster Self-Study
  • P045

  The purely thermodynamic anti-prionic mode of action for the treatment of neurodegenerative diseases.

  • Dieter Willbold (Jülich / DE)

   Disease models, drug development
• • Poster Self-Study
  • P046

  A Novel Chemotype of Cyclin Dependent Kinase Inhibitors Potent for Neuroblastoma Cells

  • Erik Gandalipov (Berlin / DE)

   Disease models, drug development
• • Poster Self-Study
  • P047

  Anti-inflammatory and Anti-oxidative Effects of STW 42 and Root Extract of Althaea officinalis L. on endothelial cells, fibroblasts and macrophages in vitro

  • Olaf Kelber (Darmstadt / DE)

   Disease models, drug development
• • Poster Self-Study
  • P048

  Elucidating missing X factors to understand sex bias in cardiovascular diseas

  • Sarah Hoelzl (Munich / DE)

   Disease models, drug development
• • Poster Self-Study
  • P049

  Effects of STW 3-VI (St. John's wort) on the paracrine signaling between neurons and microglia under pro-inflammatory conditions in vitro

  • Olaf Kelber (Darmstadt / DE)

   Disease models, drug development
• • Poster Self-Study
  • P050

  Assessment of immunogenicity in mice and cross-species activity of an engineered complement regulator

  • Christoph Schmidt (Ulm / DE)

   Disease models, drug development
• • Poster Self-Study
  • P051

  Diabetes impairs β-adrenergic signal transduction in the remote myocardium during the reparative phase after ischemia/reperfusion injury

  • Florian Funk (Düsseldorf / DE)

   Disease models, drug development
• • Poster Self-Study
  • P052

  Identification of key lncRNAs in cardiac resident macrophages using pooled CRISPR screens

  • Niklas Petzold (Munich / DE)

   Disease models, drug development
• • Poster Self-Study
  • P053

  A long non-coding RNA that regulates MHCII expression in cardiac macrophages

  • Lara Althaus (Munich / DE)

   Disease models, drug development
• • Poster Self-Study
  • P054

  A high-throughput radioligand receptor binding assay for the evaluation of therapeutic candidates for the treatment of nerve agent poisoning

  • Fabian Springer (Munich / DE)

   Disease models, drug development
• • Poster Self-Study
  • P055

  Screening for cardiomyocyte and fibroblast specific compound activity in a novel induced pluripotent stem cell high-content-screening platform.

  • Guobin Bao (Goettingen / DE)
  • Gabriela L. Santos (Goettingen / DE)
  • Branimir Berečić (Goettingen / DE)

   Disease models, drug development
• • Poster Self-Study
  • P056

  Force-generating skeletal muscle organoids recapitulate normal and perturbed human muscle development

  • Malte Rinn (Goettingen / DE)

   Disease models, drug development
• • Poster Self-Study
  • P057

  OLEAF4VALUE: Protective effects of olive (Olea europaea L.) leave extracts in the model organism Caenorhabditis elegans

  • Wim Wätjen (Halle (Saale) / DE)

   Disease models, drug development